ARGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARGX is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to deploy. The stock has a clear bullish technical setup, strong analyst support, and no recent negative news or insider/congress pressure. With the shares still below most Wall Street targets and major catalysts ahead, I would buy now rather than wait for a better entry.
ARGX is in a bullish trend. The MACD histogram is positive and expanding, showing strengthening momentum. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports an uptrend. RSI_6 at 68.916 is near the upper end of neutral, indicating momentum is strong but not yet deeply overbought. Price at 977.92 is above pivot 895.527 and has broken through R1 at 939.778, with next resistance near R2 at 967.116 already surpassed intraday context and further upside potential toward higher levels. Overall, the trend favors continuation higher.
["No negative news in the past week, so sentiment remains clean.", "Wells Fargo highlighted ARGX as a Q3 tactical idea and sees it as a next $100B biotech.", "Multiple analysts raised price targets recently, including BofA to $1,088 and Wells Fargo to $1,291.", "Upcoming Phase 3 myositis readout in Q3 2026 is a major event-driven catalyst.", "Recent label expansion in generalized myasthenia gravis broadens the addressable market."]
["No recent news flow to create a fresh near-term catalyst this week.", "Short-term pattern data suggests possible weakness over the next week and month despite the strong trend.", "RSI is elevated enough to show momentum is already extended relative to its recent range.", "No recent congress trading, insider buying, or influential figure accumulation to add confirmation."]
No usable latest-quarter financial snapshot was provided due to an error, so I cannot assess the most recent quarter's revenue or earnings trends directly. Based on the analyst commentary, the business is still viewed as growing well, with Wells Fargo specifically citing durable Vyvgart growth and a path to over $6B in revenue in FY26. The latest quarter season was not provided in the dataset.
Wall Street is clearly positive on ARGX. Recent notes show repeated Buy/Overweight ratings and rising price targets: BofA to $1,088, Wells Fargo to $1,291, Morgan Stanley to $1,180, Stifel to $1,255, and Evercore to $1,059. The overall pros view is that ARGX has strong long-term revenue potential and an important Q3 myositis catalyst that could drive a re-rating. The cons view is mainly that some near-term expectations may already be elevated and the stock has had a strong run, but the balance of analyst opinion remains bullish. Intellectia Proprietary Trading Signals
